Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies...

Full description

Bibliographic Details

Published in:	Blood Vol. 139; no. 6; p. 835
Main Authors:	Cavo, Michele, San-Miguel, Jesus, Usmani, Saad Z, Weisel, Katja, Dimopoulos, Meletios A, Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J, Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W C J, Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, Munshi, Nikhil
Format:	Journal Article
Language:	English
Published:	United States 10.02.2022
Subjects:	Aged Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease-Free Survival Humans Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm, Residual - diagnosis Neoplasm, Residual - drug therapy Prognosis Progression-Free Survival Treatment Outcome
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!